Guidance, NICE advice and quality standards in development

Showing 41 to 50 of 310

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]	Technology appraisal guidance	13 November 2024
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Technology appraisal guidance	5 March 2025
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	TBC